Protaryx™ Medical Welcomes David Mester as New CEO, Spearheading Innovative Advancements in Transseptal Access Technology

[Baltimore Maryland, September 11, 2023] – Protaryx Medical, a pioneering leader in medical device innovation, proudly announces the appointment of David Mester, MBA as its new Chief Executive Officer (CEO). With a remarkable career spanning over 30 years in the structural heart medical device industry, David Mester brings a wealth of experience and expertise to guide Protaryx into a new era of growth and innovation.

Protaryx Medical is renowned for its groundbreaking Protaryx Transseptal Access Device, a cutting-edge technology that revolutionizes transseptal procedures, providing streamlined access to the left side of the heart through the fossa ovalis. What sets the Protaryx device apart is its unique integration of access and transseptal crossing functions into a single device, whether used independently or alongside therapy devices. This innovative approach optimizes workflow efficiency and enhances patient outcomes.

Prior to joining Protaryx Medical, David Mester held pivotal senior business and technical leadership roles at esteemed organizations, including Sequoia Medical, Xeltis, Gore Medical, CarboMedics, and ViVitro Labs. His impactful career has been dedicated to advancing innovative materials and delivery systems for heart valve applications. Notably, he led the acquisition of new technologies and played an instrumental role in forming a new business unit at Gore Medical to explore novel heart valve technology.

David’s leadership prowess extends to overseeing First-in-Human and Early Feasibility Studies for emerging technologies, as well as leading numerous successful regulatory submissions for cardiovascular products. He is a respected figure in the industry, with active participation in regulatory sponsored working groups and a longstanding membership with the Association for the Advancement of Medical Instrumentation (AAMI) for ISO 5840WG TC150/SC2.

“David Mester’s exceptional track record in driving innovation and leading transformative initiatives in the structural heart medical device industry makes him the perfect fit to lead Protaryx Medical into its next phase of growth,” said Jim Gammie, MD, Founder and Officer of Protaryx. “His extensive experience in business leadership, technical expertise, and his commitment to advancing innovation to improve patient care align seamlessly with our mission to redefine procedural outcomes”.

David Mester’s academic journey includes studies at St. Edwards University in business and applied science, as well as an MBA from Louisiana State University.

With David Mester at the helm, Protaryx Medical is poised to continue pushing boundaries, developing cutting-edge technologies, and improving patient outcomes in the realm of structural heart interventions.

To further strengthen Protaryx leadership team, Protaryx would like to announce the appointment of Peter Boyd, JD, MBA to the Protaryx Board of Directors.  Peter Boyd is a healthcare entrepreneur with a background in business, science and law.  He was a co-founding member of Harpoon Medical where he negotiated and managed all aspects of a complex structured financing and the subsequent nine-figure acquisition by Edwards Lifesciences. Peter Boyd has worked an associate at Latham & Watkins in Silicon Valley in the emerging company and M&A practice groups, co-founded various startups including ReGeleTec, Inc., Sonnest, Inc., and Wheelhouse Ventures, and is an advisor to multiple startups including CoapTech and NeoProgen. Peter Boyd received his JD/MBA from the University of Virginia and BS in Biology from University of North Carolina.

For media inquiries, please contact:

[Media Contact Name] [Media Contact Title] [Company Name] [Email Address] [Phone Number]

About Protaryx Medical:

Protaryx Medical is an innovative medical device company focused on advancing access and procedural efficiency in structural heart interventions. The company’s flagship product, the Protaryx Transseptal Access Device, represents a breakthrough in transseptal procedures, streamlining access to the left side of the heart and optimizing workflow efficiency. Protaryx Medical is dedicated to driving innovation and improving patient care in the field of structural heart medical devices. The company is headquartered in Baltimore, Maryland, with engineering operations in Minneapolis, Minnesota. For more information, please visit